Published in PPAR Res on January 01, 2008
Curcumin inhibits transforming growth factor-β1-induced EMT via PPARγ pathway, not Smad pathway in renal tubular epithelial cells. PLoS One (2013) 1.07
PPARs Mediate Lipid Signaling in Inflammation and Cancer. PPAR Res (2008) 0.96
A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer (2012) 0.95
The investigation of mitogen-activated protein kinase phosphatase-1 as a potential pharmacological target in non-small cell lung carcinomas, assisted by non-invasive molecular imaging. BMC Cancer (2010) 0.91
Chemotherapy and chemoprevention by thiazolidinediones. Biomed Res Int (2015) 0.85
Breaking the mold: transcription factors in the anucleate platelet and platelet-derived microparticles. Front Immunol (2015) 0.84
PPARs: Interference with Warburg' Effect and Clinical Anticancer Trials. PPAR Res (2012) 0.83
Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium Retention. PPAR Res (2015) 0.81
DNA damage in exfoliated cells and histopathological alterations in the urinary tract of mice exposed to cigarette smoke and treated with chemopreventive agents. Carcinogenesis (2012) 0.80
Expression of the PAX8/PPARγ Fusion Protein Is Associated with Decreased Neovascularization In Vivo: Impact on Tumorigenesis and Disease Prognosis. Genes Cancer (2010) 0.79
Expression of Peroxisome Proliferator Activated Receptor gamma in Prostatic Adenocarcinoma. J Korean Med Sci (2015) 0.78
Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. Invest New Drugs (2013) 0.77
Role of renal proximal tubule transport in thiazolidinedione-induced volume expansion. World J Nephrol (2012) 0.76
Phosphorylation of PPARγ at Ser84 promotes glycolysis and cell proliferation in hepatocellular carcinoma by targeting PFKFB4. Oncotarget (2016) 0.75
Loss of PTEN Facilitates Rosiglitazone-Mediated Enhancement of Platinum(IV) Complex LA-12-Induced Apoptosis in Colon Cancer Cells. PLoS One (2015) 0.75
Antiadipogenic effects of subthermal electric stimulation at 448 kHz on differentiating human mesenchymal stem cells. Mol Med Rep (2016) 0.75
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene (2007) 11.85
The MAPK signaling cascade. FASEB J (1995) 10.81
A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science (2005) 9.80
Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature (2006) 9.36
A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest (2007) 8.54
Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature (1998) 8.33
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta (2006) 7.33
Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature (2003) 6.87
The many faces of PPARgamma. Cell (2005) 6.24
Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol (2003) 5.87
PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem (2001) 5.85
The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors (2006) 5.58
WNT signaling pathway and stem cell signaling network. Clin Cancer Res (2007) 4.24
The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta (2006) 4.06
PPAR-gamma regulates osteoclastogenesis in mice. Nat Med (2007) 3.59
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol (2007) 3.39
Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer (2006) 3.19
Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med (1998) 3.13
Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer (2004) 2.93
Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med (1998) 2.90
Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell (1999) 2.71
Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr Biol (1999) 2.65
An overview on biological mechanisms of PPARs. Pharmacol Res (2005) 2.43
Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta (2006) 2.28
Activation of MEK/ERK signaling promotes adipogenesis by enhancing peroxisome proliferator-activated receptor gamma (PPARgamma ) and C/EBPalpha gene expression during the differentiation of 3T3-L1 preadipocytes. J Biol Chem (2002) 2.21
p14-MP1-MEK1 signaling regulates endosomal traffic and cellular proliferation during tissue homeostasis. J Cell Biol (2006) 2.15
Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem Pharmacol (2005) 2.14
Modulation of PPAR activity via phosphorylation. Biochim Biophys Acta (2007) 2.11
Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev (2001) 2.09
Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol (2004) 2.08
Sef is a spatial regulator for Ras/MAP kinase signaling. Dev Cell (2004) 2.04
A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. Biochem Biophys Res Commun (2003) 2.03
Retracted Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci U S A (2002) 2.01
Role of PPARgamma in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1/Cip1), during adipogenesis. J Biol Chem (1999) 1.96
Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res (2001) 1.96
Functional interaction between peroxisome proliferator-activated receptor gamma and beta-catenin. Mol Cell Biol (2006) 1.95
APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci U S A (2002) 1.89
Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol (2004) 1.88
Nuclear receptors: integration of multiple signalling pathways through phosphorylation. Cell Signal (2003) 1.72
Cyclin D3 promotes adipogenesis through activation of peroxisome proliferator-activated receptor gamma. Mol Cell Biol (2005) 1.63
Interferon-gamma-mediated activation and ubiquitin-proteasome-dependent degradation of PPARgamma in adipocytes. J Biol Chem (2001) 1.61
Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity. Dev Cell (2003) 1.60
Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma. Mol Cell Biol (2006) 1.59
PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev (2004) 1.58
Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways. Mol Cancer Ther (2006) 1.57
Phosphorylation of PPARs: from molecular characterization to physiological relevance. Biochimie (2005) 1.55
Mek1/2 MAPK kinases are essential for Mammalian development, homeostasis, and Raf-induced hyperplasia. Dev Cell (2007) 1.54
Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf (2007) 1.50
The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther (2005) 1.46
Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene (2006) 1.45
Mek2 is dispensable for mouse growth and development. Mol Cell Biol (2003) 1.44
ERK MAP kinase in G cell cycle progression and cancer. Cancer Sci (2006) 1.41
Antitumorigenic effect of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor gamma. J Biol Chem (2006) 1.40
PPARgamma influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis. Carcinogenesis (2004) 1.38
MAPK kinases as nucleo-cytoplasmic shuttles for PPARgamma. Cell Cycle (2007) 1.37
Peroxisome proliferator-activated receptor gamma activation can regulate beta-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway. J Biol Chem (2004) 1.36
Mitogen-activated protein kinase kinase 1-dependent Golgi unlinking occurs in G2 phase and promotes the G2/M cell cycle transition. Mol Biol Cell (2006) 1.34
The MEK1 scaffolding protein MP1 regulates cell spreading by integrating PAK1 and Rho signals. Mol Cell Biol (2005) 1.34
PPARs in diseases: control mechanisms of inflammation. Curr Med Chem (2005) 1.33
Mek1 alters epidermal growth and differentiation. Cancer Res (2004) 1.33
Regulation of SRC-3 intercompartmental dynamics by estrogen receptor and phosphorylation. Mol Cell Biol (2007) 1.32
Palmitate-mediated downregulation of peroxisome proliferator-activated receptor-gamma coactivator 1alpha in skeletal muscle cells involves MEK1/2 and nuclear factor-kappaB activation. Diabetes (2006) 1.32
Cdk4 promotes adipogenesis through PPARgamma activation. Cell Metab (2005) 1.31
ERK1c regulates Golgi fragmentation during mitosis. J Cell Biol (2006) 1.28
Protein-protein interactions in the regulation of the extracellular signal-regulated kinase. Mol Biotechnol (2005) 1.28
Dok1 mediates high-fat diet-induced adipocyte hypertrophy and obesity through modulation of PPAR-gamma phosphorylation. Nat Med (2008) 1.27
Expression of activated MEK1 in differentiating epidermal cells is sufficient to generate hyperproliferative and inflammatory skin lesions. J Invest Dermatol (2004) 1.27
PPAR dual agonists: are they opening Pandora's Box? Pharmacol Res (2007) 1.26
A family of fatty acid binding receptors. DNA Cell Biol (2005) 1.25
PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis (2005) 1.25
Site-specific cancer risk due to diabetes mellitus history: evidence from the Japan Collaborative Cohort (JACC) Study. Asian Pac J Cancer Prev (2006) 1.25
The potential of antidiabetic thiazolidinediones for anticancer therapy. Expert Opin Investig Drugs (2006) 1.24
Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer (2003) 1.20
Is B-Raf a good therapeutic target for melanoma and other malignancies? Cancer Res (2008) 1.18
Hyperglycemia enhances adipogenic induction of lipid accumulation: involvement of extracellular signal-regulated protein kinase 1/2, phosphoinositide 3-kinase/Akt, and peroxisome proliferator-activated receptor gamma signaling. Endocrinology (2007) 1.18
Impact of genetic variation of PPARgamma in humans. Mol Genet Metab (2004) 1.17
The PPAR-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis (2006) 1.17
Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling. Mol Pharmacol (2005) 1.16
Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System. BMC Med (2007) 1.16
The clinicopathological and prognostic significance of membrane type 1 matrix metalloproteinase (MT1-MMP) and MMP-9 according to their localization in invasive breast carcinoma. Histopathology (2007) 1.16
Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer. Expert Opin Investig Drugs (2005) 1.16
Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells. J Biol Chem (2002) 1.14
Rsk2 allosterically activates estrogen receptor alpha by docking to the hormone-binding domain. EMBO J (2001) 1.13
Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. Mol Pharmacol (2005) 1.13
Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate (2002) 1.13
Glucocorticoid receptor-JNK interaction mediates inhibition of the JNK pathway by glucocorticoids. EMBO J (2003) 1.11
PPAR-gamma agonist increase gefitinib's antitumor activity through PTEN expression. Lung Cancer (2005) 1.11
A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. Mol Endocrinol (2005) 1.11
Chemopreventive effect of peroxisome proliferator-activated receptor gamma on gastric carcinogenesis in mice. Cancer Res (2005) 1.10
GPR40, a free fatty acid receptor on pancreatic beta cells, regulates insulin secretion. Hepatol Res (2005) 1.10
Pro-MMP-2 activation by the PPARgamma agonist, ciglitazone, induces cell invasion through the generation of ROS and the activation of ERK. FEBS Lett (2007) 1.10
PPARgamma1 attenuates cytosol to membrane translocation of PKCalpha to desensitize monocytes/macrophages. J Cell Biol (2007) 1.10
Peroxisome proliferator-activated receptor gamma promotes epithelial to mesenchymal transformation by Rho GTPase-dependent activation of ERK1/2. J Biol Chem (2006) 1.08
PPARgamma and colon and rectal cancer: associations with specific tumor mutations, aspirin, ibuprofen and insulin-related genes (United States). Cancer Causes Control (2006) 1.08
Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. Cancer Res (2005) 1.07
Oleate promotes the proliferation of breast cancer cells via the G protein-coupled receptor GPR40. J Biol Chem (2005) 1.06
PPAR-gamma agonists induce the expression of VEGF and its receptors in cultured cardiac myofibroblasts. Cardiovasc Res (2007) 1.05
Effects of active MEK1 expression in vivo. Cancer Lett (2005) 1.05
The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors (2006) 5.58
The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta (2006) 4.06
Vimentin-dependent spatial translocation of an activated MAP kinase in injured nerve. Neuron (2005) 3.09
The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions. Methods Mol Biol (2010) 2.72
Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene (2002) 2.50
DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity: a link to histone acetylation. Mol Cell (2007) 2.48
The ERK cascade: a prototype of MAPK signaling. Mol Biotechnol (2005) 2.45
CXCL12 secretion by bone marrow stromal cells is dependent on cell contact and mediated by connexin-43 and connexin-45 gap junctions. Nat Immunol (2011) 2.05
The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation. Biochim Biophys Acta (2010) 1.85
The ERK Cascade: Distinct Functions within Various Subcellular Organelles. Genes Cancer (2011) 1.74
Identification and characterization of a general nuclear translocation signal in signaling proteins. Mol Cell (2008) 1.73
Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma. Mol Cell Biol (2006) 1.59
Vimentin binding to phosphorylated Erk sterically hinders enzymatic dephosphorylation of the kinase. J Mol Biol (2006) 1.57
The mitogen-activated protein kinase signaling cascade: from bench to bedside. Isr Med Assoc J (2002) 1.44
Interactions of beta and gamma ENaC with Nedd4 can be facilitated by an ERK-mediated phosphorylation. J Biol Chem (2002) 1.37
MAPK kinases as nucleo-cytoplasmic shuttles for PPARgamma. Cell Cycle (2007) 1.37
The subcellular localization of MEK and ERK--a novel nuclear translocation signal (NTS) paves a way to the nucleus. Mol Cell Endocrinol (2009) 1.37
Atypical PKC-zeta regulates SDF-1-mediated migration and development of human CD34+ progenitor cells. J Clin Invest (2005) 1.36
ERK1c regulates Golgi fragmentation during mitosis. J Cell Biol (2006) 1.28
Protein-protein interactions in the regulation of the extracellular signal-regulated kinase. Mol Biotechnol (2005) 1.28
Activation of MAPK cascades by GnRH: ERK and Jun N-terminal kinase are involved in basal and GnRH-stimulated activity of the glycoprotein hormone LHbeta-subunit promoter. Endocrinology (2002) 1.20
Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proc Natl Acad Sci U S A (2007) 1.18
Nuclear extracellular signal-regulated kinase 1 and 2 translocation is mediated by casein kinase 2 and accelerated by autophosphorylation. Mol Cell Biol (2011) 1.17
Mechanism of short-term ERK activation by electromagnetic fields at mobile phone frequencies. Biochem J (2007) 1.16
BMP-mediated inhibition of FGF signaling promotes cardiomyocyte differentiation of anterior heart field progenitors. Development (2010) 1.14
A positive role of the PI3-K/Akt signaling pathway in PC12 cell differentiation. Mol Cells (2004) 1.11
The ERK signaling cascade--views from different subcellular compartments. Biofactors (2009) 1.11
Extracellular signal-regulated kinase 1c (ERK1c), a novel 42-kilodalton ERK, demonstrates unique modes of regulation, localization, and function. Mol Cell Biol (2004) 1.07
Extracellular signal-regulated kinase, Jun N-terminal kinase, p38, and c-Src are involved in gonadotropin-releasing hormone-stimulated activity of the glycoprotein hormone follicle-stimulating hormone beta-subunit promoter. Endocrinology (2004) 1.07
Retracted Regulation of p53: intricate loops and delicate balances. Biochem Pharmacol (2002) 1.05
Retracted Calcium-mediated interactions regulate the subcellular localization of extracellular signal-regulated kinases. J Biol Chem (2008) 1.04
Regulation of p53: intricate loops and delicate balances. Ann N Y Acad Sci (2002) 1.01
Glycolysis and glucose transporter 1 as markers of response to hormonal therapy in breast cancer. Int J Cancer (2003) 1.00
Casein kinase 2 specifically binds to and phosphorylates the carboxy termini of ENaC subunits. Eur J Biochem (2002) 1.00
Calcium regulates ERK signaling by modulating its protein-protein interactions. Commun Integr Biol (2008) 0.99
Phosphomimetic mutants of pigment epithelium-derived factor with enhanced antiangiogenic activity as potent anticancer agents. Cancer Res (2010) 0.98
Manipulation of redox signaling in mammalian cells enabled by controlled photogeneration of reactive oxygen species. J Cell Sci (2005) 0.97
Activation of mitogen-activated protein kinase (MAPK) by GnRH is cell-context dependent. Mol Cell Endocrinol (2006) 0.94
Down-regulation of steroidogenic response to gonadotropins in human and rat preovulatory granulosa cells involves mitogen-activated protein kinase activation and modulation of DAX-1 and steroidogenic factor-1. J Clin Endocrinol Metab (2003) 0.94
The ERK cascade as a prototype of MAPK signaling pathways. Methods Mol Biol (2004) 0.94
ERK as a model for systems biology of enzyme kinetics in cells. Curr Biol (2013) 0.94
Identification of extracellular signal-regulated kinase 1/2 and p38 MAPK as regulators of human sperm motility and acrosome reaction and as predictors of poor spermatozoan quality. J Biol Chem (2008) 0.93
MEK5 and ERK5 are localized in the nuclei of resting as well as stimulated cells, while MEKK2 translocates from the cytosol to the nucleus upon stimulation. J Cell Sci (2004) 0.93
Extracellular phosphorylation converts pigment epithelium-derived factor from a neurotrophic to an antiangiogenic factor. Blood (2004) 0.92
Retracted c-Src is activated by the epidermal growth factor receptor in a pathway that mediates JNK and ERK activation by gonadotropin-releasing hormone in COS7 cells. J Biol Chem (2003) 0.91
Retracted Pigment epithelium-derived factor and its phosphomimetic mutant induce JNK-dependent apoptosis and p38-mediated migration arrest. J Biol Chem (2010) 0.91
Specific phosphorylation and activation of ERK1c by MEK1b: a unique route in the ERK cascade. Genes Dev (2009) 0.90
The Ras inhibitors caveolin-1 and docking protein 1 activate peroxisome proliferator-activated receptor γ through spatial relocalization at helix 7 of its ligand-binding domain. Mol Cell Biol (2011) 0.89
A preformed signaling complex mediates GnRH-activated ERK phosphorylation of paxillin and FAK at focal adhesions in L beta T2 gonadotrope cells. Mol Endocrinol (2009) 0.89
Extracellular signal-regulated kinase and c-Src, but not Jun N-terminal kinase, are involved in basal and gonadotropin-releasing hormone-stimulated activity of the glycoprotein hormone alpha-subunit promoter. Endocrinology (2003) 0.87
Differential role of PKC isoforms in GnRH and phorbol 12-myristate 13-acetate activation of extracellular signal-regulated kinase and Jun N-terminal kinase. Endocrinology (2010) 0.87
Distinct pathways for the involvement of WNK4 in the signaling of hypertonicity and EGF. FEBS J (2008) 0.85
Retracted Gq protein-induced apoptosis is mediated by AKT kinase inhibition that leads to protein kinase C-induced c-Jun N-terminal kinase activation. J Biol Chem (2011) 0.85
Stimulated nuclear import by β-like importins. F1000Prime Rep (2013) 0.85
Variable phosphorylation states of pigment-epithelium-derived factor differentially regulate its function. Blood (2005) 0.84
Beta-like importins mediate the nuclear translocation of mitogen-activated protein kinases. Mol Cell Biol (2013) 0.84
Gonadotropin-releasing hormone in apoptosis of prostate cancer cells. Cancer Lett (2005) 0.84
Determination of ERK activity: anti-phospho-ERK antibodies and in vitro phosphorylation. Methods Mol Biol (2010) 0.81
Calcium regulation of EGF-induced ERK5 activation: role of Lad1-MEKK2 interaction. PLoS One (2010) 0.80
ERK signaling in colorectal cancer: a preliminary report on the expression of phosphorylated ERK and the effects of radiation therapy. Am J Clin Oncol (2008) 0.80
Mxi2 sustains ERK1/2 phosphorylation in the nucleus by preventing ERK1/2 binding to phosphatases. Biochem J (2012) 0.80
ATM-dependent activation of the gene encoding MAP kinase phosphatase 5 by radiomimetic DNA damage. Oncogene (2002) 0.80
Use of inhibitors in the study of MAPK signaling. Methods Mol Biol (2004) 0.79
Ligand interaction scan (LIScan) in the study of ERK8. Biochem Biophys Res Commun (2010) 0.79
Maturation-promoting factor governs mitogen-activated protein kinase activation and interphase suppression during meiosis of rat oocytes. Biol Reprod (2002) 0.79
Mechanisms of gonadotropin desensitization. Mol Cell Endocrinol (2002) 0.79
Gonadotropin-releasing hormone induces apoptosis of prostate cancer cells: role of c-Jun NH2-terminal kinase, protein kinase B, and extracellular signal-regulated kinase pathways. Cancer Res (2004) 0.79
Differential signaling of the GnRH receptor in pituitary gonadotrope cell lines and prostate cancer cell lines. Mol Cell Endocrinol (2013) 0.78
Deletion of alloreactive T cells by veto cytotoxic T lymphocytes is mediated through extracellular signal-regulated kinase phosphorylation. Transplantation (2010) 0.78
Determination of ERK activity: antiphospho-ERK antibodies, in vitro phosphorylation, and in-gel kinase assay. Methods Mol Biol (2004) 0.77
Nuclear localization of phosphorylated ERK1 and ERK2 as markers for the progression of ovarian cancer. Int J Oncol (2011) 0.77
Role of non-phosphorylated activation loop residues in determining ERK2 dephosphorylation, activity, and subcellular localization. J Biol Chem (2007) 0.77
SB203580 induces prolonged B-Raf activation and promotes neuronal differentiation upon EGF treatment of PC12 cells. Biochemistry (Mosc) (2004) 0.76
Ecto- and exo-protein kinases in Schistosoma mansoni: regulation of surface phosphorylation by acetylcholine and identification of the alpha subunit of CKII as a major secreted protein kinase. J Parasitol (2005) 0.76
Conjugates of gonadotropin releasing hormone (GnRH) with carminic acid: Synthesis, generation of reactive oxygen species (ROS) and biological evaluation. Bioorg Med Chem (2008) 0.76
The detection of MAPK signaling. Curr Protoc Mol Biol (2006) 0.76
A 50-kDa ERK-like protein is up-regulated by a dual altered peptide ligand that suppresses myasthenia gravis-associated responses. Proc Natl Acad Sci U S A (2006) 0.76
Retracted Two initiation sites of early detection of colon cancer, revealed by localization of pERK1/2 in the nuclei or in aggregates at the perinuclear region of tumor cells. Int J Oncol (2011) 0.75
ERK1b, a 46-kDa ERK isoform that is differentially regulated by MEK. J Biol Chem (2017) 0.75
Role of dynamin, Src, and Ras in the protein kinase C-mediated activation of ERK by gonadotropin-releasing hormone. J Biol Chem (2017) 0.75
The detection of MAPK signaling. Curr Protoc Cell Biol (2005) 0.75
Altered regulation of ERK1b by MEK1 and PTP-SL and modified Elk1 phosphorylation by ERK1b are caused by abrogation of the regulatory C-terminal sequence of ERKs. J Biol Chem (2017) 0.75
The ERK signaling cascade inhibits gonadotropin-stimulated steroidogenesis. J Biol Chem (2017) 0.75
Two initiation sites of early detection of colon cancer revealed by localization of pERK1/2 in the nuclei or in aggregates at the perinuclear region of the tumor cells. Acta Histochem (2013) 0.75
c-Src is activated by the epidermal growth factor receptor in a pathway that mediates JNK and ERK activation by gonadotropin-releasing hormone in COS7 cells. J Biol Chem (2017) 0.75
Calcium-mediated interactions regulate the subcellular localization of extracellular signal-regulated kinases. J Biol Chem (2017) 0.75
Pigment epithelium-derived factor and its phosphomimetic mutant induce JNK-dependent apoptosis and p38-mediated migration arrest. J Biol Chem (2017) 0.75
The extra-cellular signal regulated kinases ERK1 and ERK2 segregate displaying distinct spatiotemporal characteristics in activated mast cells. Biochim Biophys Acta (2013) 0.75
Shmuel Shaltiel. FEBS Lett (2003) 0.75
Involvement of the activation loop of ERK in the detachment from cytosolic anchoring. J Biol Chem (2017) 0.75
Gq protein-induced apoptosis is mediated by AKT kinase inhibition that leads to protein kinase C-induced c-Jun N-terminal kinase activation. J Biol Chem (2017) 0.75